SCHEMBL6202706

SCHEMBL6202706

c1ccc(CN2CCC3CC(C2)CN(Cc2ccccc2)C3)cc1

nearest known ligand 0.83

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.56
BCHE P06276 4/20 0.55
BACE1 P56817 4/20 0.55
CCR3 P51677 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C19 P33261 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CXCR3 P49682 1/20 0.54
SIGMAR1 Q99720 1/20 0.53
FUCA1 P04066 2/20 0.51
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
CCR5 P51681 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21793950 0.91 FUCA1 (0.56) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL5750271 0.91 FUCA1 (0.56) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL21793953 0.91 FUCA1 (0.56) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL2955795 0.91 FUCA1 (0.60) ACHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20488466 0.87 FUCA1 (0.60) ACHECYP1A2CYP3A4CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL20488123 0.85 FUCA1 (0.58) ACHEALDH1A1CXCR3SIGMAR1FUCA1
SCHEMBL9271837 0.83 FUCA1 (0.49) ACHECCR3CYP1A2CYP3A4CYP2D6
SCHEMBL6202941 0.83 FUCA1 (0.60) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL25900100 0.82 MC4R (0.55) ACHESIGMAR1FUCA1
SCHEMBL6204569 0.80 CHRNA7 (0.48) ACHEBCHEBACE1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397365-B1 HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS NEUROSEARCH AS (DK) 2005-02-16 EP disclosed
US-20040147505-A1 Novel heteroaryl-diazabicyclo alkanes as cns-modulators NEUROSEARCH A/S (DK) 2004-07-29 US disclosed
EP-1397365-A1 NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS NeuroSearch A/S (DK) 2004-03-17 EP disclosed
WO-2002096911-A1 NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS NEUROSEARCH A/S (DK) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147505-A1 Novel heteroaryl-diazabicyclo alkanes as cns-modulators CHRNA3, CHRNA5, CHRNA2 ACHE 27/4885BCHE 153/4885BACE1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.